Shafic Makumbi

419 total citations
5 papers, 45 citations indexed

About

Shafic Makumbi is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Shafic Makumbi has authored 5 papers receiving a total of 45 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 3 papers in Virology and 2 papers in Epidemiology. Recurrent topics in Shafic Makumbi's work include HIV/AIDS drug development and treatment (5 papers), HIV Research and Treatment (3 papers) and HIV/AIDS Research and Interventions (2 papers). Shafic Makumbi is often cited by papers focused on HIV/AIDS drug development and treatment (5 papers), HIV Research and Treatment (3 papers) and HIV/AIDS Research and Interventions (2 papers). Shafic Makumbi collaborates with scholars based in Zimbabwe, United Kingdom and Uganda. Shafic Makumbi's co-authors include Godfrey Musoro, Diana M. Gibb, Carlo Giaquinto, Abbas Lugemwa, David M. Burger, Pablo Rojo, Angela Colbers, Adeodata Kekitiinwa, Deborah Ford and Hilda Mujuru and has published in prestigious journals such as Clinical Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes and The Lancet HIV.

In The Last Decade

Shafic Makumbi

4 papers receiving 45 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shafic Makumbi Zimbabwe	4	39	22	15	8	8	5	45
Abbas Lugemwa United Kingdom	4	42 1.1×	32 1.5×	18 1.2×	8 1.0×	14 1.8×	5	69
Pascale Perfezou France	3	20 0.5×	20 0.9×	5 0.3×	3 0.4×	13 1.6×	4	31
Kenneth Sutton United States	5	75 1.9×	64 2.9×	4 0.3×	8 1.0×	14 1.8×	15	87
Maurizio Milesi Italy	4	24 0.6×	17 0.8×	4 0.3×	3 0.4×	14 1.8×	5	44
Hellen Musana Uganda	4	31 0.8×	34 1.5×	11 0.7×	1 0.1×	9 1.1×	4	54
Blair Thedinger United States	3	44 1.1×	26 1.2×	4 0.3×	2 0.3×	11 1.4×	4	51
Ann Sarah Walker United Kingdom	3	25 0.6×	13 0.6×	4 0.3×		5 0.6×	7	29
Jayne Gould United Kingdom	4	21 0.5×	7 0.3×	3 0.2×	12 1.5×	2 0.3×	5	37
Vicente Estrada Pérez Spain	4	28 0.7×	14 0.6×	2 0.1×	8 1.0×	3 0.4×	7	37
Zachary Strongin United States	3	26 0.7×	31 1.4×		3 0.4×	5 0.6×	3	35

Countries citing papers authored by Shafic Makumbi

Since Specialization

Citations

This map shows the geographic impact of Shafic Makumbi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shafic Makumbi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shafic Makumbi more than expected).

Fields of papers citing papers by Shafic Makumbi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shafic Makumbi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shafic Makumbi. The network helps show where Shafic Makumbi may publish in the future.

Co-authorship network of co-authors of Shafic Makumbi

This figure shows the co-authorship network connecting the top 25 collaborators of Shafic Makumbi. A scholar is included among the top collaborators of Shafic Makumbi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shafic Makumbi. Shafic Makumbi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Waalewijn, Hylke, Roeland E. Wasmann, Alasdair Bamford, et al.. (2025). Brief Report: Pharmacokinetic Data of Atazanavir/Ritonavir in Second-Line Treatment of Children Living With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 100(1). 83–87.

2.

Waalewijn, Hylke, Alexander J. Szubert, Roeland E. Wasmann, et al.. (2023). First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Clinical Infectious Diseases. 77(6). 875–882. 7 indexed citations

3.

Waalewijn, Hylke, Alexander J. Szubert, Chishala Chabala, et al.. (2023). Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial. Clinical Infectious Diseases. 77(9). 1312–1317. 3 indexed citations

4.

Waalewijn, Hylke, Man K. Chan, Hilda Mujuru, et al.. (2022). Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. The Lancet HIV. 9(5). e341–e352. 14 indexed citations

5.

Moore, Cecilia L., Hilda Mujuru, Shafic Makumbi, et al.. (2020). Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. The Lancet HIV. 7(8). e533–e544. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact